[Abstract] 

We are interested in developing new bio-therapeutics such as antibody and exosome. Firstly, we have selected an anti-Tspan12 antibody to reduce vaso-proliferative retinopathy using human combinatorial antibody libraries. Anti-angiogenic biologicals represent an important concept for the treatment of vaso-proliferative diseases. However, the need for continued treatment, the presence of non-responders and the risk of long-term side-effects limits the success of existing therapeutic agents. In this study, we found that Tspan12/β-catenin signaling is critical for the progression of vaso-proliferative disease. The newly developed anti-Tspan12 antibody has therapeutic effects in vaso-proliferative retinopathy enhancing the potency of existing anti-VEGF agents. In addition, recently, we selected anti-GFRAL antagonist & agonist antibodies for the treatment of the cancer-associated cachexia and severe obesity respectively. Although, both antibodies are still under functional characterization and affinity maturation, they have high potential to be developed as new drugs.